Barry Gritz
Psychiatry · Houston, TXNPI 1487635892
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $704,645 of the $792,315 with a category attached, or 88.9%. 36 manufacturers reported payments, led by AbbVie at 50.1% of the total. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,863 payments — averaging $425.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$397K
- Otsuka America Pharmaceutical, Inc.$209K
- Supernus Pharmaceuticals, Inc.$88K
- Vanda Pharmaceuticals Inc.$49K
- Takeda Pharmaceuticals U.S.A., Inc.$21K
- Corium, LLC$10K
- plus $19K from 30 others
What the payments were for
- Consulting fees$5,6701%
- Speaking & faculty fees$704,64589%
- Travel & lodging$50,8026%
- Food & beverage$31,0794%
- Education$1190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$792,315 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 13 | $107,510 |
| ZyprexaOlanzapine | 25 | $42,996 |
| VraylarCariprazine Hcl | 20 | $37,770 |
| RexultiBrexpiprazole | 20 | $31,200 |
| TrintellixVortioxetine Hydrobromide | 27 | $26,531 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 402 | $14,985 |
| Lisdexamfetamine Dimesylate | 64 | $11,995 |
| AdderallDextroamphetamine/Amphetamine | 12 | $7,594 |
| Fluvoxamine Maleate ErFluvoxamine Maleate | 12 | $7,165 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 92 | $6,094 |
| MydayisDextroamphetamine/Amphetamine | 17 | $5,623 |
| Bupropion XlBupropion Hcl | 179 | $5,000 |
| Adderall XrDextroamphetamine/Amphetamine | 13 | $4,690 |
| Focalin XrDexmethylphenidate Hcl | 12 | $2,383 |
| Alprazolam | 227 | $2,306 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $954 | $107,51013 claims |
| AbbVieVraylar | $397,203 | $37,77020 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Adderall | $20,646 | $34,12539 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $209,468 | $31,20020 claims |
| Shire North American Group IncMydayis | $135 | $5,62317 claims |
| Almatica Pharma LLCSertraline Hcl | $195 | $50966 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Houston
- Matthew BramsHouston$1.5M
- Frank ChenHouston$941K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Aaron PetersonHouston$700K
- Ayesha RashidHouston$641K
- Lawrence GinsbergHouston$502K
- Kathy FlanaganHouston$443K
- Rayan Al JurdiHouston$359K
- Prashant GajwaniHouston$355K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.